Donanemab (Kisunla)

Introduction

Donanemab (brand name Kisunla; development code LY3002813) is a humanized IgG1 monoclonal antibody developed by Eli Lilly and Company for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in July 2024, donanemab became the second anti-amyloid antibody to receive traditional FDA approval, following lecanemab, representing a significant expansion in disease-modifying treatment options for Alzheimer's disease[@sims2023].

This entity profile provides a comprehensive overview of donanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: [Donanemab (Kisunla) — Therapeutics](/therapeutics/donanemab).

Molecular Characteristics

Antibody Class and Structure

Donanemab is a humanized IgG1 monoclonal antibody engineered for specific targeting of pyroglutamate-modified amyloid-beta (N3pG-Aβ). This specific targeting distinguishes it from other anti-amyloid antibodies and contributes to its unique efficacy and safety profile[@ovod2017].

Key molecular properties:

Introduction

Donanemab (brand name Kisunla; development code LY3002813) is a humanized IgG1 monoclonal antibody developed by Eli Lilly and Company for the treatment of early Alzheimer's disease (AD). Approved by the U.S. Food and Drug Administration (FDA) in July 2024, donanemab became the second anti-amyloid antibody to receive traditional FDA approval, following lecanemab, representing a significant expansion in disease-modifying treatment options for Alzheimer's disease[@sims2023].

This entity profile provides a comprehensive overview of donanemab as a therapeutic entity within the NeuroWiki knowledge base, covering its molecular characteristics, mechanism of action, clinical development, and position within the landscape of Alzheimer's disease therapeutics. For detailed clinical trial data, efficacy analyses, and safety profiles, refer to the dedicated therapeutics page: [Donanemab (Kisunla) — Therapeutics](/therapeutics/donanemab).

Molecular Characteristics

Antibody Class and Structure

Donanemab is a humanized IgG1 monoclonal antibody engineered for specific targeting of pyroglutamate-modified amyloid-beta (N3pG-Aβ). This specific targeting distinguishes it from other anti-amyloid antibodies and contributes to its unique efficacy and safety profile[@ovod2017].

Key molecular properties:

| Property | Value |
|----------|-------|
| Antibody type | Humanized IgG1 |
| Molecular weight | ~150 kDa |
| Target | N3pG-Aβ (pyroglutamate-modified Aβ) |
| Target form | Deposited amyloid plaques |
| Affinity for N3pG-Aβ | High (sub-nanomolar) |
| Affinity for monomeric Aβ | Low |
| Fc region | Native (not engineered) |

Target Specificity: Pyroglutamate-Modified Aβ

Donanemab's defining feature is its specific binding to N3pG-Aβ (also written as N3pE-Aβ), a truncated and post-translationally modified form of amyloid-beta:

• N3pG-Aβ forms: Aβ peptides with N-terminal truncation at glutamate (E) or glutamate-3 (E3), followed by cyclization to form pyroglutamate
• Enrichment in plaques: N3pG-Aβ is highly enriched in mature amyloid plaques compared to soluble Aβ
• Pathological significance: These modified forms are highly fibrillar and resistant to degradation, making them key constituents of amyloid deposits

• Lecanemab: Prefers soluble Aβ protofibrils
• Aducanumab: Binds to multiple Aβ forms including monomers
• Donanemab: Selectively targets N3pG-Aβ in plaques

Mechanism of Action

Primary Mechanisms

Donanemab exerts its therapeutic effects through several interconnected mechanisms[@bain2023]:

1. Plaque-Directed Binding
Donanemab selectively binds to N3pG-Aβ within deposited amyloid plaques, marking them for immune-mediated clearance. This binding is highly specific for the plaque environment rather than soluble Aβ species.

2. Fcγ Receptor-Mediated Phagocytosis
The antibody-opsonized plaque complexes engage Fcγ receptors on microglia, triggering phagocytosis and lysosomal degradation. This represents the primary clearance mechanism for donanemab-bound amyloid.

3. Antibody-Dependent Cellular Cytotoxicity (ADCC)
The Fc region of donanemab can engage natural killer (NK) cells and other immune effector cells, potentially contributing to plaque clearance through ADCC mechanisms.

4. Plaque Destabilization
Evidence suggests donanemab may destabilize existing amyloid plaques, facilitating their conversion to soluble aggregates that can be cleared through the mechanisms described above.

Relationship to Microglial Function

Like lecanemab, donanemab's efficacy is intimately connected to microglial biology. The antibody's plaque clearance depends on functional microglial phagocytosis, involving:

• TREM2: Essential for microglial phagocytosis of opsonized amyloid
• CD36: Scavenger receptor facilitating Aβ uptake
• Fcγ receptors: Mediate antibody-dependent cellular phagocytosis

Limited-Duration Treatment Paradigm

One of donanemab's most innovative features is its limited-duration treatment approach:

This approach offers several potential advantages:

• Reduced cumulative ARIA risk
• Lower treatment burden and costs
• Improved patient convenience
• Potential for disease modification with finite treatment

Clinical Development History

Phase I Studies (2014-2017)

Phase I clinical trials established:

• Safety and tolerability in early AD patients
• Dose-proportional pharmacokinetics
• Dose-dependent amyloid plaque reduction
• Optimal dosing: 350 mg monthly

Phase II TRAILBLAZER-ALZ (2017-2020)

The Phase II TRAILBLAZER-ALZ trial enrolled 272 patients with early AD[@mintun2021]:

• Primary endpoint: Change in Integrated Alzheimer's Disease Rating Scale (iADRS) at 76 weeks
• Result: Significant plaque reduction and slowing of cognitive decline
• Key innovation: Pioneered biomarker-guided treatment discontinuation approach

Phase III TRAILBLAZER-ALZ 2 (2021-2023)

The pivotal Phase III TRAILBLAZER-ALZ 2 trial enrolled 1,736 patients with early AD[@sims2023]:

• Primary endpoint: Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) at 18 months
• Result: 35.6% slowing of clinical decline in low/medium tau group
• Amyloid reduction: 80.2% reduction in Centiloid (86 to 17)
• Key finding: Greater benefit in patients with lower baseline tau pathology

TRAILBLAZER-ALZ 3 and Extensions (2024-Present)

Following FDA approval, development continues with:

• TRAILBLAZER-ALZ 3: Prevention trial in preclinical AD
• TRAILBLAZER-ALZ 4: Imaging outcomes study
• Long-term extensions: Safety and efficacy monitoring

Regulatory Status

Global Approvals

| Region | Status | Date |
|--------|--------|------|
| United States | FDA approved | July 2024 |
| Japan | Approved | October 2024 |
| United Kingdom | Under review | - |
| European Union | Under review | - |
| Canada | Under review | - |

Indication

Donanemab is indicated for the treatment of early Alzheimer's disease, specifically:

• Mild cognitive impairment (MCI) due to Alzheimer's disease
• Mild Alzheimer's disease dementia

Clinical Efficacy

Primary Trial Results

In TRAILBLAZER-ALZ 2[@sims2023]:

| Endpoint | Donanemab | Placebo | Treatment Effect |
|----------|-----------|---------|-------------------|
| CDR-SB change (18 mo) | 2.97 | 4.04 | -1.07 (35.6% slowing) |
| Amyloid reduction | 86→17 Centiloid | Minimal | 80.2% reduction |
| CSF p-tau181 | -17.3% | +3.4% | Significant reduction |

Tau Stratification

Donanemab's efficacy varies by baseline tau burden[@mintun2021]:

| Tau Level | CDR-SB Benefit | Clinical Meaning |
|-----------|-----------------|------------------|
| Low/Medium | Greater benefit (35.6% slowing) | Earlier intervention more effective |
| High | Moderate benefit | Advanced disease less responsive |

This stratification approach allows for personalized treatment decisions based on disease stage.

Safety Profile

Amyloid-Related Imaging Abnormalities (ARIA)[@heath2024]

| ARIA Type | Donanemab | Placebo |
|-----------|-----------|---------|
| ARIA-E (edema) | ~24% | ~2% |
| ARIA-H (hemorrhage) | ~7% | ~2% |

• Most cases mild to moderate in severity
• Incidence highest in first 12 weeks of treatment
• Monitoring required with MRI at baseline and regular intervals

ARIA Risk Factors

| Risk Factor | Impact |
|-------------|--------|
| APOE ε4 homozygosity | Highest ARIA risk |
| APOE ε4 heterozygosity | Moderate ARIA risk |
| Prior cerebral microhemorrhages | Increased risk |

Infusion-Related Reactions

• Incidence approximately 8-10%
• Most reactions mild to moderate
• Managed with premedication and infusion rate adjustment

Position in Alzheimer's Disease Therapeutics

Comparison with Other Anti-Amyloid Antibodies

| Feature | Donanemab | Lecanemab | Aducanumab |
|---------|-----------|-----------|------------|
| Target | N3pG-Aβ plaques | Protofibrils | Mixed forms |
| Treatment approach | Limited duration | Continuous | Continuous |
| Dosing | 350 mg monthly | 10 mg/kg biweekly | 10 mg/kg monthly |
| Amyloid reduction | ~80% | ~81% | ~60% |
| CDR-SB benefit | 0.70-1.07 | 0.45 | 0.39 |
| ARIA-E rate | ~24% | ~13% | ~35% |

Therapeutic Positioning

Donanemab occupies a unique position in the AD therapeutic landscape:

Treatment Selection Considerations

Choice between donanemab and lecanemab depends on:

• Patient preference: Continuous vs. limited-duration treatment
• ARIA risk: Patient's ARIA risk profile
• Tau status: Baseline tau PET results
• Plaque burden: Degree of amyloid pathology

Therapeutic Considerations

Patient Selection Criteria

Optimal candidates for donanemab therapy meet the following criteria:

• Clinical: Early AD (MCI or mild dementia), CDR 0.5-1.0
• Biomarker: Confirmed amyloid pathology via PET or CSF
• Tau status: Low to medium tau burden preferred
• Functional: Independent or minimally assisted ADL
• Safety: No contraindication to MRI monitoring

Monitoring Requirements

Patients receiving donanemab require regular monitoring:

• Baseline MRI: Within 6 months before first infusion
• Follow-up MRI: Week 12, Week 24, then as clinically indicated
• APOE genotyping: Informs ARIA risk assessment
• Amyloid PET: For treatment discontinuation decisions

Cross-Links to NeuroWiki Entities

Related Proteins and Pathways

• [Amyloid-Beta](/proteins/amyloid-beta) — Primary therapeutic target
• [N3pG-Aβ](/proteins/n3pg-amyloid-beta) — Specific target form
• [Tau Protein](/proteins/tau) — Downstream pathology
• [APOE](/proteins/apoe-protein) — Genetic risk modifier
• [TREM2](/genes/trem2) — Microglial receptor for amyloid clearance

Related Diseases and Conditions

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Target indication
• [MCI (Mild Cognitive Impairment)](/diseases/mci) — Earlier disease stage

Related Mechanisms

• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis) — Foundational mechanism
• [Amyloid Plaque Formation](/mechanisms/amyloid-plaque-formation) — Plaque biology
• [Microglial Phagocytosis](/mechanisms/microglial-phagocytosis) — Clearance pathway
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway) — Related pathway
• [Neuroinflammation in AD](/mechanisms/neuroinflammation-alzheimers) — Inflammatory consequences

Related Therapeutics

• [Lecanemab (Leqembi) — Entity](/entities/lecanemab) — Alternative anti-amyloid antibody
• [Aducanumab (Aduhelm) — Entity](/entities/aducanumab) — Earlier anti-amyloid antibody
• [Donanemab — Therapeutics](/therapeutics/donanemab) — Detailed clinical data

Key Clinical Trials

| Trial | Phase | Population | Status | Key Results |
|-------|-------|------------|--------|-------------|
| TRAILBLAZER-ALZ | II | Early AD (n=272) | Complete | iADRS improvement |
| TRAILBLAZER-ALZ 2 | III | Early AD (n=1,736) | Complete | Primary endpoint met |
| TRAILBLAZER-ALZ 3 | III | Preclinical AD | Recruiting | Prevention trial |
| TRAILBLAZER-ALZ 4 | III | Early AD | Recruiting | Imaging outcomes |

Research Gaps and Future Directions

Unanswered Questions

Despite donanemab's approval, several important questions remain:

Ongoing Research

Active research areas include:

• TRAILBLAZER-ALZ 3: Prevention trial in preclinical populations
• Retreatment protocols: Studies on restarting treatment if plaques return
• Subcutaneous delivery: Exploring alternative administration routes

References

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta Protein](/proteins/amyloid-beta)
• [Lecanemab (Leqembi) — Entity](/entities/lecanemab)
• [Donanemab — Therapeutics](/therapeutics/donanemab)
• [Anti-Amyloid Immunotherapy](/mechanisms/amyloid-immunotherapy-pathway)
• [TREM2 Microglial Pathway](/mechanisms/trem2-microglial-pathway)
• [Microglia — Cell Type](/cell-types/microglia)

External Links

• [Kisunla Official Website](https://www.kisunla.com)
• [ClinicalTrials.gov: Donanemab](https://clinicaltrials.gov/search?term=Donanemab)
• [FDA Approval Announcement](https://www.fda.gov/drugs/news-events-human-drug-alerts/fda-approves-kisunla-donanemab-alzheimers-disease-treatment)
• [Eli Lilly Neuroscience](https://www.lilly.com)
• [Lilly Donanemab Product Information](https://pi.lilly.com)

Allen Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — Brain gene expression data for amyloid and tau pathology
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression data for microglia and neurons